A detailed history of First Bank & Trust transactions in Castle Biosciences Inc stock. As of the latest transaction made, First Bank & Trust holds 9,164 shares of CSTL stock, worth $257,508. This represents 0.05% of its overall portfolio holdings.

Number of Shares
9,164
Holding current value
$257,508
% of portfolio
0.05%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$17.4 - $31.47 $159,453 - $288,391
9,164 New
9,164 $261,000
Q2 2022

Jul 22, 2022

BUY
$16.0 - $45.99 $59,328 - $170,530
3,708 Added 90.22%
7,818 $172,000
Q1 2022

Apr 29, 2022

BUY
$33.17 - $46.98 $24,313 - $34,436
733 Added 21.71%
4,110 $184,000
Q4 2021

Feb 01, 2022

BUY
$39.06 - $67.58 $91,556 - $158,407
2,344 Added 226.91%
3,377 $145,000
Q3 2021

Oct 18, 2021

BUY
$60.13 - $77.6 $36,619 - $47,258
609 Added 143.63%
1,033 $69,000
Q2 2021

Aug 10, 2021

BUY
$50.07 - $76.78 $21,229 - $32,554
424 New
424 $31,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $739M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track First Bank & Trust Portfolio

Follow First Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on First Bank & Trust with notifications on news.